EVIAMO

This brand name is authorized in South Africa.

Active ingredients

The drug EVIAMO contains one active pharmaceutical ingredient (API):

`1`	Ruxolitinib UNII `82S8X8XX8H` - RUXOLITINIB
	Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2. These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.
	Read more about Ruxolitinib

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EJ01	Ruxolitinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EJ Janus-associated kinase (JAK) inhibitors
Discover more medicines within L01EJ01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ZA	Health Products Regulatory Authority	48/34/0900, 48/34/0901, 48/34/0902

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.